NASDAQ:ABMD - Abiomed Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $238.25
  • Forecasted Upside: -27.67 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$329.38
▲ +11.07 (3.48%)
1 month | 3 months | 12 months
Get New Abiomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABMD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$238.25
▼ -27.67% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Abiomed in the last 3 months. The average price target is $238.25, with a high forecast of $320.00 and a low forecast of $155.00. The average price target represents a -27.67% upside from the last price of $329.38.
Hold
The current consensus among 6 polled investment analysts is to hold stock in Abiomed. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/24/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/15/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$280.00 ➝ $320.00High
i
12/15/2020Morgan StanleyBoost Price TargetUnderweight$217.00 ➝ $238.00Medium
i
10/12/2020SVB LeerinkLower Price TargetMarket Perform$335.00 ➝ $280.00Medium
i
Rating by D. Antalffy at SVB Leerink LLC
8/7/2020Morgan StanleyBoost Price TargetUnderweight$152.00 ➝ $217.00Medium
i
Rating by David Lewis at Morgan Stanley
8/7/2020SVB LeerinkBoost Price TargetMarket Perform$280.00 ➝ $335.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
7/13/2020OTR GlobalUpgradePositiveHigh
i
5/28/2020SVB LeerinkBoost Price TargetMarket Perform$195.00 ➝ $225.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
5/27/2020BTIG ResearchDowngradeHoldHigh
i
Rating by Marie Thibault at BTIG Research
5/1/2020Morgan StanleyBoost Price TargetUnderweight$149.00 ➝ $152.00Medium
i
Rating by David Lewis at Morgan Stanley
4/27/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$220.00 ➝ $175.00High
i
Rating by Danielle Antalffy at SVB Leerink LLC
3/27/2020Morgan StanleyLower Price TargetUnderweight$165.00 ➝ $149.00Low
i
Rating by David Lewis at Morgan Stanley
3/23/2020Piper SandlerReiterated RatingBuy$240.00High
i
Rating by Matthew O'Brien at Piper Sandler
3/23/2020StephensLower Price TargetOverweight$240.00 ➝ $155.00High
i
2/11/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight$198.00 ➝ $165.00High
i
2/6/2020BTIG ResearchInitiated CoverageHoldHigh
i
12/17/2019Morgan StanleyLower Price TargetEqual Weight$215.00 ➝ $198.00Low
i
11/1/2019SVB LeerinkBoost Price TargetOutperform$195.00 ➝ $240.00High
i
10/29/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
9/30/2019William BlairReiterated RatingBuyLow
i
Rating by Margaret Kaczor at William Blair
8/2/2019William BlairReiterated RatingBuyLow
i
Rating by Margaret Kaczor at William Blair
8/2/2019GuggenheimDowngradeBuy ➝ NeutralMedium
i
8/1/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$325.00 ➝ $215.00Medium
i
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
5/7/2019BTIG ResearchReiterated RatingBuyLow
i
5/3/2019SunTrust BanksReiterated RatingBuy$340.00Low
i
1/22/2019BTIG ResearchReiterated RatingBuy$400.00Low
i
1/2/2019Morgan StanleyLower Price TargetOverweight ➝ Overweight$496.00 ➝ $461.00High
i
11/7/2018Morgan StanleyUpgradeEqual ➝ Equal Weight$396.00 ➝ $496.00Medium
i
11/2/2018BTIG ResearchUpgradeNeutral ➝ Buy$450.00Low
i
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$370.00 ➝ $396.00High
i
6/22/2018Piper Jaffray CompaniesBoost Price TargetOverweight$360.00 ➝ $480.00High
i
5/29/2018Jefferies Financial GroupBoost Price TargetBuy$460.00Medium
i
5/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$360.00High
i
5/1/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$259.00 ➝ $320.00Medium
i
4/4/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$332.00Medium
i
Rating by Issac Ro at The Goldman Sachs Group, Inc.
2/16/2018SunTrust BanksReiterated RatingBuy$370.00N/A
i
2/4/2018BTIG ResearchReiterated RatingHoldHigh
i
2/2/2018SVB LeerinkBoost Price TargetOutperform$300.00Low
i
2/2/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$204.00 ➝ $259.00Low
i
2/2/2018GuggenheimReiterated RatingBuy$280.00Medium
i
2/1/2018Jefferies Financial GroupReiterated RatingBuy$300.00Medium
i
2/1/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$220.00 ➝ $300.00Medium
i
1/19/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $265.00Low
i
1/12/2018Jefferies Financial GroupBoost Price TargetBuy$250.00Medium
i
1/4/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
i
12/21/2017Jefferies Financial GroupBoost Price TargetBuy$208.00 ➝ $220.00Medium
i
11/1/2017SunTrust BanksReiterated RatingBuy$195.00N/A
i
10/29/2017BTIG ResearchReiterated RatingHoldN/A
i
10/26/2017Piper Jaffray CompaniesBoost Price TargetOverweight$200.00N/A
i
10/16/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
10/12/2017SVB LeerinkReiterated RatingOutperform$180.00 ➝ $200.00N/A
i
9/29/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$195.00High
i
9/29/2017Jefferies Financial GroupBoost Price TargetBuy$175.00 ➝ $208.00High
i
8/29/2017Piper Jaffray CompaniesReiterated RatingBuy$160.00Low
i
8/29/2017Jefferies Financial GroupReiterated RatingBuy$175.00Low
i
8/4/2017Jefferies Financial GroupBoost Price TargetBuy$165.00 ➝ $175.00Low
i
7/27/2017Piper Jaffray CompaniesReiterated RatingOverweight$145.00 ➝ $160.00Medium
i
7/10/2017Morgan StanleyReiterated RatingEqual Weight$135.00 ➝ $140.00Low
i
7/4/2017Piper Jaffray CompaniesSet Price Target$145.00Low
i
6/8/2017William BlairReiterated RatingOutperform ➝ OutperformLow
i
Rating by M. Kaczor at William Blair
4/6/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$145.00Medium
i
3/30/2017SVB LeerinkBoost Price TargetOutperform$140.00 ➝ $150.00Low
i
1/8/2017BTIG ResearchReiterated RatingBuy$170.00N/A
i
12/6/2016GuggenheimInitiated CoverageBuy$150.00N/A
i
9/28/2016SVB LeerinkReiterated RatingOutperform$125.00N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
8/9/2016Jefferies Financial GroupBoost Price TargetBuy$130.00 ➝ $145.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
7/29/2016Jefferies Financial GroupBoost Price TargetBuy$125.00 ➝ $130.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
6/10/2016Jefferies Financial GroupReiterated RatingBuy$125.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
5/5/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
5/4/2016SVB LeerinkReiterated RatingOutperform$120.00 ➝ $125.00N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
4/17/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
4/10/2016BenchmarkReiterated RatingBuy$145.00N/A
i
4/9/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
4/8/2016SVB LeerinkReiterated RatingBuyN/A
i
3/22/2016Jefferies Financial GroupReiterated RatingBuy$125.00N/A
i
2/5/2016Piper Jaffray CompaniesReiterated RatingHold$75.00 ➝ $90.00N/A
i
Rating by Brooks West at Piper Jaffray Companies
2/5/2016BTIG ResearchReiterated RatingBuy$110.00N/A
i
Rating by Sean Lavin at BTIG Research
2/4/2016BenchmarkBoost Price TargetBuy$133.00 ➝ $145.00N/A
i
(Data available from 1/15/2016 forward)
Abiomed logo
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Read More

Today's Range

Now: $329.38
$321.43
$329.85

50 Day Range

MA: $294.61
$258.45
$324.67

52 Week Range

Now: $329.38
$119.01
$330.80

Volume

12,219 shs

Average Volume

322,786 shs

Market Capitalization

$14.88 billion

P/E Ratio

72.39

Dividend Yield

N/A

Beta

1.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Abiomed?

The following Wall Street sell-side analysts have issued research reports on Abiomed in the last twelve months: BTIG Research, Morgan Stanley, OTR Global, Piper Sandler, Stephens, SVB Leerink LLC, and Zacks Investment Research.

What is the current price target for Abiomed?

4 Wall Street analysts have set twelve-month price targets for Abiomed in the last year. Their average twelve-month price target is $238.25, suggesting a possible downside of 25.2%. SVB Leerink LLC has the highest price target set, predicting ABMD will reach $320.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $155.00 for Abiomed in the next year.

What is the current consensus analyst rating for Abiomed?

Abiomed currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ABMD, but not buy more shares or sell existing shares.

What other companies compete with Abiomed?

How do I contact Abiomed's investor relations team?

Abiomed's physical mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider's listed phone number is 978-646-1400 and its investor relations email address is ir@abiomed.com. The official website for Abiomed is www.abiomed.com.